Department of Nephrology, Renmin Hospital of Wuhan University, Wuhan, China.
Clin Exp Immunol. 2024 Oct 16;218(2):120-135. doi: 10.1093/cei/uxae068.
Ongoing therapeutic advances in antineutrophil cytoplasmic antibody-associated vasculitis (AAV) have significantly reduced the risk of death in AAV, but 30%-50% of patients still relapse. Relapse is a major problem in these diseases, leading to increased morbidity and mortality. It is, therefore, necessary to find predictors of relapse at the end of the remission induction and maintenance phases in order to personalize treatment.
抗中性粒细胞胞浆抗体相关性血管炎（AAV）的治疗进展不断，显著降低了 AAV 的死亡风险，但仍有 30%-50%的患者会复发。复发是这些疾病的主要问题，导致发病率和死亡率增加。因此，有必要在缓解诱导和维持阶段结束时寻找复发的预测因子，以便进行个体化治疗。
